Cutroneo, Paola Maria
Arzenton, Elena
Furci, Fabiana
Scapini, Fabio
Bulzomì, Maria
Luxi, Nicoletta
Caminati, Marco
Senna, Gianenrico
Moretti, Ugo
Trifirò, Gianluca http://orcid.org/0000-0003-1147-7296
Funding for this research was provided by:
Università degli Studi di Verona
Article History
Accepted: 1 February 2024
First Online: 15 March 2024
Declarations
:
: Open access funding provided by Università degli Studi di Verona within the CRUI-CARE Agreement.
: Gianluca Trifirò has served on advisory boards/seminars funded by SANOFI, Eli Lilly, AstraZeneca, Abbvie, Servier, Mylan, Gilead and Amgen in the past three years; he was the scientific director of a Master’s program on pharmacovigilance, pharmacoepidemiology and real-world evidence which has received non-conditional grants from various pharmaceutical companies; he coordinated a pharmacoepidemiology team at the University of Messina until October 2020, which has received funding for conducting observational studies from various pharmaceutical companies (Boehringer Ingelheim, Daichii Sankyo, PTC Pharmaceuticals). He is also scientific coordinator of the academic spin-off ‘INSPIRE srl’ which has received funding for conducting observational studies from contract research organizations (RTI Health Solutions, Pharmo Institute N.V.). None of the above-mentioned activities are related to the topic of the manuscript. The other authors have no conflict of interest to disclose.
: VigiBase, the WHO global database of ICSRs, is the source of our information. The information comes from a variety of sources, and the probability that the suspected adverse event is drug-related is not the same in all cases; the information does not represent the opinion of the UMC or WHO.
: The datasets generated and/or analyzed in the current study are available in the VigiBase repository. The data presented in this study are obtainable on request from the corresponding author.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors contributed equally to this work. All authors read and approved the final manuscript.